Extended Data Fig. 1: Clinical course of Jo-1+ anti-synthetase syndrome. | Nature Medicine

Extended Data Fig. 1: Clinical course of Jo-1+ anti-synthetase syndrome.

From: BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells

Extended Data Fig. 1

a, Clinical manifestations before and three months after the first CD19-CAR T-cell therapy, daratumumab therapy and BCMA-CAR T-cell therapy. b, Serum creatinine kinase (CK) levels during various treatment regimens. The horizontal dotted line indicates the upper limit of normal range (<170 U/l). CYC = cyclophosphamide, RTX = rituximab, IVIG = intravenous immunoglobulins, TAC = tacrolimus, TO = tofacitinib, BA = baricitnib, MTX = methotrexate, LEN = lenabasum, OC = ocrelizumab, TOC = tocilizumab, MMF = mycophenolate mofetil, CAR = chimeric antigen receptor, DARA = Daratumumab. c, Longitudinal assessment of anti-Jo1 autoantibody titers. d, Muscle strength as indicated by Manual Muscle Testing 8 (MMT8) score.

Back to article page